Article in Human immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Loren GragertTulane University School of Medicine, Department of Medicine, Division of Biomedical Informatics and Genomics, New Orleans, LA, United States of America.
Abeer MadboulyCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, United States of America.
Pradeep BashyalCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, United States of America.
Kim WadsworthNMDP, Minneapolis, MN, United States of America.
Jane KempenichNMDP, Minneapolis, MN, United States of America.
Yung-Tsi BolonCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, United States of America.
Martin MaiersCIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, United States of America. Electronic address: mmaiers@nmdp.org.
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5M
NTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3M
The landscape of HLA mediated variation in health and immunityR01AI158861 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLLENBACH, JILL ALLISON · 2021 to 2025
$3.5M
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosageU01AI184132 · NIAID · NATIONAL MARROW DONOR PROGRAM · PI JEFFERY J AULETTA, Michael A Pulsipher · 2024 to 2026
$3.2M
HLA Immunogenetics and kidney allograft outcomesR01AI173095 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Malek Kamoun · 2023 to 2026
$3.1M
MHC and KIR Sequencing and Association Analyses in the iGeneTRAiN StudiesU01AI152960 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI KAMOUN, MALEK, KEATING, BRENDAN JAMES · 2020 to 2024
$2.8M
Increasing Equity and Utility in Deceased Donor Kidney Allocation with HLA Molecular MatchingR01DK139240 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOREN GRAGERT, Michal A Mankowski · 2024 to 2026
$2.1M
Designing ABO-Compatible US Kidney Allocation - Resubmission - 1R01DK140336 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOREN GRAGERT, Michal A Mankowski · 2025 to 2026
$1.7M
BMT Core - Pediatric Transplantation and Cellular Therapy Consortium (PTCTC): Providing Clinical Trial Access For Children With Life Threatening DiseasesUG1HL174426 · NHLBI · NATIONAL MARROW DONOR PROGRAM · PI Leslie S Kean, Heather E Stefanski · 2024 to 2026
$513k
PROVIDE RABBITS, RATS, MICE, HAMSTERS, GERBILS, GUINEA PIGS27307C0011 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
The human leukocyte antigen (HLA) system is the primary determinant of donor selection in allogeneic hematopoietic cell transplantation (HCT) and plays a central role in solid organ transplantation, immune-mediated disease studies, evolutionary population genetics, and immunotherapy. Large-scale sampling of registry participants reflecting major US ancestry groups allows for characterization of the complex landscape of HLA haplotype diversity for the classical HLA class I (HLA-A, HLA-B, HLA-C) and HLA class II (HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1) genes. Here we present nine-locus classical HLA allele and haplotype frequency estimates for five broad (Black, White, Asian or Pacific Islander, Hispanic and Native American) and 21 detailed US populations based on 9,671,082 donors with targeted genotyping by DNA-based methods. Frequency estimation used an expectation-maximization (EM) framework specifically adapted to handle mixed-resolution and ambiguous HLA genotyping data. Advancements in next-generation sequencing provide extensive HLA genotyping, offering new insights into the haplotype structure and diversity of the human MHC complex, expanding knowledge especially for HLA class II haplotypes. Population analyses reveal that the most common haplotypes are predominantly population-specific, with only three haplotypes shared across the top 100 lists of all five broad population groups, and that Black populations exhibit the greatest nine-locus haplotypic diversity, a pattern that persists after controlling for differences in registry sample size. These frequencies, derived from the largest US cohort to date, support clinical decision-making and research in histocompatibility, immunogenetics, and transplantation and are publicly available at https://zenodo.org/records/17966993.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Classical HLA allele and haplotype frequency estimates in US populations. · full record | OpenQuestion